Emcitate (tiratricol)
Rare Thyroid Therapeutics
ApprovedSep 28, 2026
Marketer take
An ultra-rare pediatric endocrine launch in MCT8 deficiency, where genetic diagnosis, pediatric endocrinology and neurology referrals, and advocacy groups drive patient finding.
- Sponsor company
- Rare Thyroid Therapeutics
- Indication
- To treat peripheral thyrotoxicosis in patients with MCT8 deficiency
- Therapeutic area
- Endocrinology, Rare disease
- Event
- FDA approval
- Date
- Sep 28, 2026
- Status
- Approved
- Source
- FDA page
- Last verified
- Nov 15, 2026
Dates and status come from the linked public source as of the last verified date. Spot an error or have an update?